Charles Rowland

Charles A. Rowland is currently Director at Financial Executives International Philadelphia Chapter, Independent Director at Orchard Therapeutics (Europe) Ltd. since 2018, and Independent Director at Viking Therapeutics, Inc. since 2016.
Former roles include Co-Chief Executive Officer, CFO & Executive VP at Endo Pharmaceuticals, Inc. from 2006 to 2008; President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. from 2016 to 2017; Finance Director at Bristol Myers Squibb Co. from 1985 to 1993; Independent Director at Idenix Pharmaceuticals LLC in 2014; Independent Director at DNIB Unwind, Inc. from 2015 to 2016; Independent Director at Nabriva Therapeutics Plc from 2015 to 2024; Independent Director at Vitae Pharmaceuticals LLC from 2015 to 2016; Independent Director at Generation Bio Co. from 2018 to 2026; Non-Executive Director at Akamis Bio Ltd. from 2017 to 2019; Director at Blueprint Medicines Corp.
from 2015 to 2022; Director at Bind Therapeutics from 2014 to 2016; Independent Non-Executive Director at Orchard Therapeutics Plc from 2018 to 2024; Chief Financial Officer at Biovail Corp.
from 2004 to 2006; Chief Financial Officer & Vice President at Shire ViroPharma, Inc. from 2012 to 2014; Chief Financial Officer, Treasurer & Executive VP at Endo Health Solutions, Inc. from 2006 to 2008; Vice President-Finance & Global Supply at Pharmacia Corp.
from 1998 to 2001; Vice President-Planning & Decision Support at Novartis Pharmaceuticals Corp.
from 1993 to 1998; Member-Supervisory Board at Nabriva Therapeutics GmbH from 2015 to 2017; Chief Financial Officer & Senior Vice President at Biovail Pharmaceuticals LLC in 2006; Chief Operating & Financial Officer at Breakaway Technologies, Inc. in 2004; Chief Financial Officer & Vice President at Viropharma, Inc. from 2008 to 2014.
Education includes an MBA from Rutgers State University of New Jersey in 1991 and an undergraduate degree from St. Joseph's University in 1980.